OncoDiscover Test

What is the OncoDiscover® Liquid Biopsy Test?

OncoDiscover

The OncoDiscover® Liquid Biopsy Test is India’s first indigenously developed, patented in-vitro diagnostic test to get DCG(I) approval for marketing in India.

This test is a highly specific and sensitive test that can detect, capture and enumerate Circulating Tumor Cells in very low volume of blood.

Circulating Tumor Cells (CTC) are a telltale signature of cancer metastasis.

Early Detection of Cancer.

Early Detection of Cancer

It is widely accepted that early detection of cancer is key to ensure a better outcome of cancer therapy for patients. But usually the earliest indication of cancer is due to symptoms (bleeding, lumps, non-healing wound etc) rather than the result of proactive testing. Since these symptoms are at many times improperly diagnosed or ignored, many patients are diagnosed with cancer only at a later stage.

Early diagnosis = Better prognosis

This makes treatment and recovery difficult for the patient. Cancer metastasis accounts for 90% of cancer deaths in comparison to deaths due to primary tumor. Thus, it is critical to know at the earliest possible stage about presence or spread of cancer.

In a normal ‘healthy’ human being or in a person detected with possible cancer symptoms, the OncoDiscover® Liquid Biopsy Test can be used to identify presence of cancer and the extent of cancer metastasis. This will ensure that awareness of cancer presence is at the earliest possible stage and may result in better outcome during treatment.

The OncoDiscover® Liquid Biopsy Test can detect cancer earlier and faster than traditional tests.

Detection of Cancer Relapse.

Detection of Cancer Relapse

Cancer Relapse can happen weeks, months, or even years after the primary cancer was treated. Relapse happens because cancer cells which escape from the primary tumor and invade the blood stream to form a new tumor near or at a distance from the primary tumor.

It is impossible for doctors to predict if and when the cancer will relapse.

Conventional tests have limited sensitivity or are difficult to perform on a regular basis to track the recurrence of cancer.

Similar to the primary cancer, in many cases detection of relapse is symptomatic or the recurrence is misdiagnosed as some other condition.

Cancer relapse is bad news because the cancer may have spread to other parts of the body, may be aggressive or widespread.

Continuous monitoring of cancer status (every 3-4 months) ensures that any relapse of cancer is caught early enough for the patient to seek effective treatment.

The OncoDiscover® Liquid Biopsy Test is the earliest and most accurate predictor of cancer recurrence.

Monitoring of cancer therapy.

Monitoring of cancer therapy

PET/CT scan is the gold standard when it comes to tumor identification in the body. But the iodine-based contrast dye used for the CT component can cause side effects, including nausea, vomiting, headache, itching, flushing, and mild rash. The other risk is of radiation exposure. The effects of radiation add up over a patient's lifetime. This can increase the risk of cancer.

Many patients are intolerant to the PET/CT and cannot undergo the scan multiple times.

The OncoDiscover® Liquid Biopsy Test is a minimally invasive test which can be performed multiple times as it needs very little blood volume. Thus this test is an excellent tool for therapy monitoring.

The test can be performed at multiple time points such as during initial checkup, pre surgery, post surgery, post chemotherapy and during follow up Since Circulating Tumor Cells (CTC) present in patient blood are enumerated (counted) by this test, it becomes a quantitative benchmark to monitor disease progression and therapy effectiveness.

OncoDiscover® Liquid Biopsy Test provides a potent real-time monitoring system that will help in understanding the spread of cancer and the effectiveness of therapy.